青岛华赛伯曼

Huasai Boman is a clinical-stage Chinese biotechnology company specializing in the development of next-generation Tumor-Infiltrating Lymphocyte (TIL) therapies for solid tumors. Founded in 2019 and headquartered in Qingdao, the company has established a proprietary platform for the isolation, expansion, and functional enhancement of TILs to overcome the immunosuppressive tumor microenvironment. Its lead candidate, HS-ITL-01, is currently undergoing Phase 1 clinical evaluation for advanced solid tumors, with a primary focus on cervical cancer. The company operates an integrated model that includes a state-of-the-art GMP manufacturing facility designed to support the large-scale production of personalized cell therapies. Huasai Boman aims to address significant unmet medical needs in oncology by optimizing the natural immune response against various refractory cancers.